Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation

A. Gramegna (Milan, Italy), M. Contarini (Milan, Italy), S. Aliberti (Milan, Italy), G. Sotgiu (Sassari, Italy), M. Seia (Milan, Italy), L. Porcaro (Milan, Italy), A. Colombo (Milan, Italy), N. Vanoni (Milan, Italy), F. Amati (Milan, Italy), G. Pizzamiglio (Milan, Italy), M. Di Pasquale (Milan, Italy), S. Dellafiore (Milan, Italy), M. Pappalettera (Milan, Italy), C. Castellani (Verona, Italy), B. Assael (Milan, Italy), F. Blasi (Milan, Italy)

Source: International Congress 2018 – Cystic fibrosis in adults: current research
Session: Cystic fibrosis in adults: current research
Session type: Thematic Poster
Number: 1324
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Gramegna (Milan, Italy), M. Contarini (Milan, Italy), S. Aliberti (Milan, Italy), G. Sotgiu (Sassari, Italy), M. Seia (Milan, Italy), L. Porcaro (Milan, Italy), A. Colombo (Milan, Italy), N. Vanoni (Milan, Italy), F. Amati (Milan, Italy), G. Pizzamiglio (Milan, Italy), M. Di Pasquale (Milan, Italy), S. Dellafiore (Milan, Italy), M. Pappalettera (Milan, Italy), C. Castellani (Verona, Italy), B. Assael (Milan, Italy), F. Blasi (Milan, Italy). Long-term outcomes and clinical worsening in cystic fibrosis patients with at least one residual function mutation. 1324

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Clinical characteristics and disease severity of adults with cystic fibrosis with at least one residual function mutation
Source: International Congress 2018 – Cystic fibrosis in adults: current research
Year: 2018


Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease
Source: Eur Respir Rev, 29 (155) 190112; 10.1183/16000617.0112-2019
Year: 2020



Do causes influence clinical, functional and quality of life aspects on patients with bronchiectasis not associated with cystic fibrosis?
Source: International Congress 2019 – Chronic cough, a1-antitrypsin deficiency and other conditions
Year: 2019


Long-term course of lung clearance index among patients with cystic fibrosis
Source: Virtual Congress 2020 – Respiratory physiology and sleep: new approaches to diagnosis and treatment
Year: 2020


Does lung transplantation affect on the improvement of psychological status in patients with adult cystic fibrosis?
Source: International Congress 2018 – Contemporary respiratory care: symptoms, the role of the nurse and the organisation of care
Year: 2018


One-year follow-up for lung function and functional capacity in cystic fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 183s
Year: 2005

Doxycycline improves clinical outcomes during cystic fibrosis exacerbations
Source: Eur Respir J , 49 (4)  1601102; DOI: 10.1183/13993003.01102-2016
Year: 2017



Clinical and functional determinants of exercise limitation in adult patients with cystic fibrosis
Source: Annual Congress 2012 - Limiting factors in exercise
Year: 2012

Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry
Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019
Year: 2020



Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021


Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 342s
Year: 2002

Hyaluroman syntehase-2 over expression has impact in the evolution and on the prognosis of idiopathic pulmonary fibrosis patients
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012

Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis
Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019
Year: 2019



Whether low frequency of hepatobiliary abnormalities in cystic fibrosis patients is associated with anti-inflammatory treatment?
Source: Annual Congress 2008 - Cystic fibrosis: a disease with many aspects
Year: 2008

Does splenectomy in cystic fibrosis related liver disease improve lung function and nutritional status? A case series
Source: Eur Respir J 2006; 28: Suppl. 50, 263s
Year: 2006

Factors affecting progression of lung disease among patients with cystic fibrosis
Source: International Congress 2019 – Physiology of cystic fibrosis
Year: 2019


Examining the effects of the Gly551Asp mutation on CT outcomes in children with cystic fibrosis
Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring
Year: 2017


Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients?
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017

Relationship between nutritional and clinical status in adult cystic fibrosis patients
Source: Eur Respir J 2006; 28: Suppl. 50, 58s
Year: 2006

Structural determinants of long-term functional outcomes in young children with cystic fibrosis
Source: Eur Respir J, 55 (5) 1900748; 10.1183/13993003.00748-2019
Year: 2020